Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

2.

For incarcerated people, study shows gaps exist in quality of cancer care

3.

Updates from the 2022 WHO classification of kidney epithelial tumors

4.

New research uncovers link between cancer pathway and blood-retina barrier function

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot